Valuation : PTC Therapeutics, Inc.

Market Cap 5.85B 5.04B 4.73B 4.31B 8.13B 559B 8.15B 56.07B 21.88B 282B 21.96B 21.49B 936B P/E 2026 *
45.8x
P/E 2027 * 25.9x
Enterprise Value 3.98B 3.43B 3.21B 2.93B 5.53B 380B 5.55B 38.14B 14.88B 192B 14.94B 14.61B 636B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 2.7x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : PTC Therapeutics, Inc.

1 day-2.40%
1 week+0.39%
Current month+3.06%
1 month-5.91%
3 months-5.09%
6 months+2.79%
Current year-7.73%
1 week 68.02
Extreme 68.02
73.52
1 month 64.57
Extreme 64.5675
75
Current year 61.43
Extreme 61.43
90.87
1 year 49.38
Extreme 49.38
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
20/8/26
Section Six Partners
SellCompany -12,500 0.0151%
19/8/26 Other

Chairman

0 0%
17/8/26 Fiscal year

General Counsel

8,439 0.0102%
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%+0.39%+42.08%+71.87% 5.85B
-0.13%-6.44%+60.34%+112.06% 1,047B
+0.85%-0.81%+51.29%+63.13% 646B
-1.03%-3.58%+21.43%+73.10% 451B
-1.46%-4.50%+37.80%+37.41% 355B
-0.72%-2.89%+22.32%+36.62% 291B
-1.19%-2.21%+1.53%+10.79% 252B
-1.05%-1.57%+50.30%+66.55% 234B
+0.08%-1.78%-17.64%-54.36% 203B
-2.14%-0.30%+28.95%+86.27% 181B
Average -0.92%-2.37%+29.84%+50.34% 366.51B
Weighted average by Cap. -0.47%-3.45%+38.18%+65.01%

Financials

2026 *2027 *
Net sales 1.26B 1.08B 1.01B 926M 1.74B 120B 1.75B 12.03B 4.7B 60.57B 4.71B 4.61B 201B 1.37B 1.18B 1.11B 1.01B 1.9B 131B 1.91B 13.13B 5.12B 66.08B 5.14B 5.03B 219B
Net income 144M 124M 117M 106M 200M 13.79B 201M 1.38B 539M 6.96B 542M 530M 23.08B 216M 186M 175M 160M 301M 20.68B 302M 2.07B 809M 10.44B 812M 795M 34.62B
Net Debt -1.87B -1.61B -1.51B -1.38B -2.6B -179B -2.61B -17.94B -7B -90.27B -7.03B -6.87B -299B -2.15B -1.85B -1.73B -1.58B -2.98B -205B -2.99B -20.56B -8.02B -104B -8.05B -7.88B -343B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
28/08/26 US$70.09 -2.40% 692,675
27/08/26 US$71.81 -1.21% 746,330
26/08/26 US$72.69 -1.06% 533,667
25/08/26 US$73.47 +3.39% 624,463
24/08/26 US$71.06 +1.78% 897,681
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
70.09USD
Average target price
99.29USD
Spread / Average Target
+41.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock